May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Plasma Carboxyethylpyrrole and AMD Risk Genotypes
Author Affiliations & Notes
  • J. Gu
    Ophthalmic Research, Cole Eye Institute, Cleveland, Ohio
    Case Western Reserve University, Cleveland, Ohio
  • U. Narendra
    Ophthalmic Research, Cole Eye Institute, Cleveland, Ohio
  • G. Pauer
    Ophthalmic Research, Cole Eye Institute, Cleveland, Ohio
  • P. Nerone
    Ophthalmic Research, Cole Eye Institute, Cleveland, Ohio
  • S. Bamba
    Ophthalmic Research, Cole Eye Institute, Cleveland, Ohio
  • X. Yue
    Ophthalmic Research, Cole Eye Institute, Cleveland, Ohio
  • R. G. Salomon
    Case Western Reserve University, Cleveland, Ohio
  • S. A. Hagstrom
    Ophthalmic Research, Cole Eye Institute, Cleveland, Ohio
    Case Western Reserve University, Cleveland, Ohio
  • J. W. Crabb
    Ophthalmic Research, Cole Eye Institute, Cleveland, Ohio
  • Cleveland AMD Study Group
    Ophthalmic Research, Cole Eye Institute, Cleveland, Ohio
  • Footnotes
    Commercial Relationships  J. Gu, None; U. Narendra, None; G. Pauer, None; P. Nerone, None; S. Bamba, None; X. Yue, None; R.G. Salomon, Franz Biomarkers, P; S.A. Hagstrom, None; J.W. Crabb, Alcon Research LTD, Merck & Co., Johnson & Johnson, F; Alcon Research LTD, Merck & Co., C; Franz Biomarkers, P.
  • Footnotes
    Support  NIH grants EY14239, EY15638, EY16072, GM21249, Ohio BRTT 05-29, Alcon, Merck, J&J, FFB, Prevent Blindness Challenge, RPE Senior Inverstigator Award, The Steinbach Foundation,
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5161. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Gu, U. Narendra, G. Pauer, P. Nerone, S. Bamba, X. Yue, R. G. Salomon, S. A. Hagstrom, J. W. Crabb, Cleveland AMD Study Group; Plasma Carboxyethylpyrrole and AMD Risk Genotypes. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5161.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate how plasma levels of carboxyethylpyrrole (CEP) adducts and autoantibodies in patients with age-related macular degeneration (AMD) correlate with risk genotypes for AMD.

Methods: : Blood was collected from clinically documented AMD and age-matched normal, healthy donors at the Cole Eye Institute, Cleveland Clinic Foundation and Louis Stokes Cleveland VA Medical Center. Plasma CEP and CEP autoantibody titer were determined by ELISA. DNA from blood donors was genotyped by either direct sequencing or restriction analysis for select risk polymorphisms associated with AMD, including Y402H in complement factor H (CFH), R80G in complement C3, A69S in LOC387715, and SNP rs11200638 in the promoter region of HTRA serine protease 1(HTRA1). Odds ratios for elevated CEP adducts and autoantibodies were calculated with SAS 9.1 software for homozygous and heterozygous genotypes relative to the wildtype genotype.

Results: : ELISA analyses of plasma from AMD donors (n = 902) demonstrated ~50% higher mean levels of CEP immunoreactivity and ~30% higher CEP autoantibody titer relative to age-matched control donors (n = 436). Genotyping has currently been completed on 529-541 AMD plasma donors. Odds ratios for elevated CEP were as follows: CFH (ORhomo=1.5, ORhet=1.0, n = 529 AMD plasma); HTRA1 (ORhomo=1.9, ORhet=1.3, n = 537 AMD plasma); LOC387715 (ORhomo=2.0, ORhet=1.2, n = 541 AMD plasma) and complement C3 (ORhomo=0.8, ORhet=1.1, n = 532 AMD plasma).

Conclusions: : The odds of both CEP adducts and autoantibodies being elevated in AMD plasma appears to be higher for individuals homozygous for the CFH Y402H, HTRA1 and LOC 387715 risk polymorphisms for AMD. A combination of genotyping and CEP plasma may prove useful for monitoring AMD therapeutic efficacy.

Keywords: age-related macular degeneration • genetics • oxidation/oxidative or free radical damage 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×